Skip to content

Released Nov 7, 2019, before the open

10-Q filed Nov 7, 2019, 38 days after period end · 0001104659-19-060804

Q3 2019 · 10-Q
Revenue$14.25M+2,049.0% vs Q3 2018+16.3% vs Q2 2019
Net Income-$3.56MN/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.24N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$1,544,000N/M
Operating Cash Flowderived-$3,225,000N/M
Free Cash Flowderived-$3,617,000N/M
Margins · derived
Operating margin-10.8%+553.4 pt vs Q3 2018
Net margin-25.0%+777.7 pt vs Q3 2018

What the release said

The release

Same quarter

MetricQ3 2019Q3 2018Q3 2017Q3 2016
Revenue$14.25M$663.00K$7.53M$4.67M
Net Income-$3.56M-$5.32M-$11.44M-$7.29M
EPS Diluted-$0.24-$0.40-$0.09-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR